Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
NCT03761030 · New York State Psychiatric Institute · PHASE4 · terminated · last registry update 2023-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The project end date was reached prior to the full sample enrollment” | – | Registry record, New York State Psychiatric Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-05-06Also stopped (withdrawn): Mayo Clinic, Olanzapine + Placebo Administration (NCT05403580)
- 2024-04-29Phase 3 first posted: Areteia Therapeutics, Dexpramipexole Dihydrochloride (NCT06388889)
- 2024-04-23Also stopped (terminated): Mylan Pharmaceuticals Inc, Olanzapine Tablets 20 mg + Zyprexa® Tablets 20 mg (NCT00647972)
- 2024-04-19Also stopped (terminated): Marubeni Pharmaceuticals (Suzhou) Co., Ltd., Lurasidone (NCT05213143)
- 2024-04-17Phase 3 first posted: State University of New York - Upstate Medical University, Dexmedetomidine + Lorazepam (NCT06370442)
- 2024-03-29Phase 3 first posted: Qinghai Red Cross Hospital, Olanzapine 2.5 MG + Standard anti-tumor treatment (NCT06338683)
- 2024-03-26Phase 3 first posted: Fudan University, Netupitant / Palonosetron Oral Capsule [Akynzeo] + Olanzapine (NCT06331520)
- 2024-03-18Phase 3 first posted: Feixue Song, Antiemetic Therapy + Antiemetic Therapy (NCT06314906)
- 2024-03-13Also stopped (terminated): University Medical Center Groningen, Apomorphine 0.25% (2.5mg/ml) + Hydrocortisone cream 1% (NCT02230930)
- 2024-01-22Results posted on the registry: Rush University Medical Center, o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1 + Olanzapine10 mg orally daily on Days -1,0,+1 and +2 (NCT02939287)
- 2024-01-10Phase 3 first posted: M.D. Anderson Cancer Center, Olanzapine + Olanzapine (NCT06200181)
- 2024-01-10Phase 3 first posted: Jiuda Zhao, Standard antiemetic treatment + Standard antiemetic treatment (NCT06200168)
- 2023-12-18Phase 3 first posted: Corey Hawes, Cyproheptadine + Olanzapine (NCT06175273)
- 2023-12-13Phase 3 first posted: Ain Shams University, Haloperidol Injection (NCT06168773)
- 2023-11-22Results posted on the registry: Sumitomo Pharma America, Inc., APL-130277 (NCT02542696)
- 2023-11-18Results posted on the registry: InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-11-18Also stopped (terminated): InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-10-25Also stopped (withdrawn): Massachusetts General Hospital, buprenorphine transdermal delivery system (BTDS) + Placebo for BTDS patch (NCT02138357)
- 2023-09-28Results posted on the registry: AbbVie, Cariprazine + Placebo (NCT03573297)
- 2023-09-28Also stopped (terminated): Impel Pharmaceuticals, INP105 + Placebo (NCT05163717)
- 2023-09-01Also stopped (terminated): MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals, APOKYN (NCT02549573)
- 2023-06-09Phase 3 first posted: Christian Hassager, Dexamethasone + Olanzapine (NCT05895838)
- 2023-05-09Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Olanzapine 5 MG + Placebo (NCT04535141)
- 2023-05-08Results posted on the registry: Alliance for Clinical Trials in Oncology, Palonosetron Hydrochloride + Ondansetron Hydrochloride (NCT03578081)
- 2023-04-24Phase 3 first posted: Region Skane, Pramipexole (NCT05825235)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision